Fibrogen Inc. Stock
€1.08
Your prediction
Fibrogen Inc. Stock
Pros and Cons of Fibrogen Inc. in the next few years
Pros
Cons
Performance of Fibrogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fibrogen Inc. | 1.750% | 11.681% | -29.567% | -93.478% | 22.849% | -93.647% | - |
| Ironwood Pharmaceuticals | 0.670% | 2.759% | 2.055% | -22.798% | -26.961% | -18.132% | - |
| Sage Therapeutics Inc. | 0.040% | -11.648% | -24.641% | -75.363% | -42.350% | -80.719% | - |
| Novocure Ltd | 0.030% | 30.065% | 14.280% | -76.332% | 4.553% | -90.566% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.FibroGen, a company operating within the biotechnology and medical research industry, appears to be facing financial challenges based on an initial analysis of their financial statements. Although the company has successfully generated revenue, their expenses, particularly in research and development, seem to have outpaced their earnings, translating into considerable net losses over the years. It is crucial to delve deeper into the company's financials to identify the pros and cons of their current standing.
*Pros: *
Revenue growth: Over the past few years, FibroGen has experienced revenue growth. For instance, the total revenue has grown from $176.32 million in 2020 to $235.31 million in 2021, marking a positive trend in sales and possible market traction generated by their products and services.
Comments
